<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115477</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2013-09-22/2014-03-21</org_study_id>
    <secondary_id>The Swedish Cancer Society</secondary_id>
    <nct_id>NCT02115477</nct_id>
  </id_info>
  <brief_title>Lymphedema After Primary Surgery for Endometrial Cancer</brief_title>
  <acronym>LASEC</acronym>
  <official_title>Prevalence, Complications and Risk Factors for Lymphedema After Pelvic and Paraaortic Lymphadenectomy in Primary Radical Surgery for Early Stage Endometrial Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Preben Kjolhede, MD, professor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council of Southeast Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ostergotland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are

        -  to determine the prevalence, size and impact on quality of life of lymphedema of the
           lower extremities after primary radical surgery with hysterectomy +/- pelvic - and
           paraaortic lymphadenectomy in women with endometrial uterine carcinoma FIGO
           (International Federation of Gynecology and Obstetrics) stage 1 and 2

        -  to analyze risk factors for development of lymphedema in this specific group of
           patients.

      Our hypotheses are that women who have lymphadenectomy more often suffer from lymphedema,
      subjectively and objectively, and have an impaired quality of life.

      This is a Swedish multicenter study carried out in 17 departments of Obstetrics and
      Gynecology and in 3 departments of Oncology. All participants are treated according to the
      Swedish National Guidelines for Endometrial Cancer.

      130 women with endometrial cancer who have a hysterectomy with lymphadenectomy (high-risk
      endometrial carcinomas) and 130 women with endometrial cancer who have a hysterectomy without
      lymphadenectomy (low-risk endometrial carcinomas) are prospectively enrolled in the study.

      The participants are examined preoperatively and on 3 occasions postoperatively, i.e. 4-6
      weeks , 6 months and 12 months postoperatively.

      Determination of occurrence of lymphedema of the lower extremities are determined objectively
      by 1) a standardized clinical evaluation according to Bruna et al.[1] and 2) determining the
      leg volume according to the cone model by Sitzia [2] by systematically measuring of leg
      circumferences. In addition, occurrence of lymphedema is measured subjectively by the
      participants.

      On the same four occasions as the leg circumference measurements are conducted the patients
      complete two generic health related quality of life forms (the EuroQol EQ-5D and the
      Short-Form 36 SF-36) and the condition specific quality of life form for limb lymphedema
      (LYMQOL).

      Demographic and clinical data are systematically collected until one year postoperatively
      including occurrence of complications and given adjuvant oncological therapy such as chemo-
      and radiation therapy.

      On each occasion of clinical control a vaginal ultrasound examination is carried out in order
      to register pelvic and abdominal lymphocele formation or lymphatic fluid effusion
      intraabdominally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not included
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in leg volume from baseline (preoperatively) to 4-6 weeks postoperatively</measure>
    <time_frame>4-6 weeks after the primary surgery</time_frame>
    <description>Leg volume is determined by the cone model according to Sitzia by measuring leg circumferences systematically.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in leg volume from baseline (preoperatively) to 6 months postoperatively</measure>
    <time_frame>6 months after the primary surgery</time_frame>
    <description>Leg volume is determined by the cone model according to Sitzia by measuring leg circumferences systematically.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in leg volume from baseline (preoperatively) to 12 months postoperatively</measure>
    <time_frame>12 months after the primary surgery</time_frame>
    <description>Leg volume is determined by the cone model according to Sitzia by measuring leg circumferences systematically.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessment from baseline (preoperatively) to 4-6 weeks postoperatively</measure>
    <time_frame>4-6 weeks from the primary surgery</time_frame>
    <description>Quality of life measured by means of The EuroQol (EQ-5D), the Short-Form 36 (SF-36) and the condition specific quality of life form LYMQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessment from baseline (preoperatively) to 6 months postoperatively</measure>
    <time_frame>6 months from the primary surgery</time_frame>
    <description>Quality of life measured by means of The EuroQol (EQ-5D), the Short-Form 36 (SF-36) and the condition specific quality of life form LYMQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessment from baseline (preoperatively) to 12 months postoperatively</measure>
    <time_frame>12 months from the primary surgery</time_frame>
    <description>Quality of life measured by means of The EuroQol (EQ-5D), the Short-Form 36 (SF-36) and the condition specific quality of life form LYMQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an increase in leg volume of &gt; 15% 12 months postoperatively</measure>
    <time_frame>12 months after the primary surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who states they have lymphedema</measure>
    <time_frame>12 months from the primary surgery</time_frame>
    <description>Occurrence of lymphedema subjectively graded as 2 or more on an ordinal scale from 1 to 4. 1 express no swelling of the legs and 4 express severe swelling.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Risk factors for lymphedema after primary surgery with lymphadenectomy for endometrial cancer</measure>
    <time_frame>Within 12 months after the surgery</time_frame>
    <description>Risk factors defined in terms of number of lymphnodes removed, site of lymphnodes, peri- and postoperative complications, adjuvant chemotherapy, adjuvant radiation therapy, age, histopathological subtype, surgical FIGO stage, DNA-ploidy status of the tumor, comorbidity and relapse of the cancer.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Carcinoma of the Endometrium</condition>
  <condition>Hysterectomy</condition>
  <condition>Lymphadenectomy</condition>
  <arm_group>
    <arm_group_label>Group with lymphadenectomy</arm_group_label>
    <description>The group of women with high risk endometrial cancer who undergoes pelvic and/or paraaortic lymphadenectomy at primary surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group without lymphadenectomy</arm_group_label>
    <description>The group of women with low risk endometrial cancer who do not have lymphadenectomy at primary surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphadenectomy</intervention_name>
    <description>Pelvic and/or paraaortic lymphadenectomy</description>
    <arm_group_label>Group with lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All women admitted to the participating clinics for primary surgery of endometrial
        carcinoma FIGO stage 1 and 2 will be asked to participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years.

          -  Women with endometrial carcinoma preoperatively evaluated to be uterine cancer FIGO
             stage1 or 2 who are planned for primary radical surgery including simple or radical
             hysterectomy, bilateral salpingoophorectomy,+/- pelvic and paraaortic lymphadenectomy
             and +/- omentectomy with curative intention.

          -  WHO performance status ≤ 2.

          -  Understand and speak Swedish fluently

          -  Accept to participate in the study by giving verbal and written informed consent.

        Exclusion Criteria:

          -  Sarcoma of the uterus

          -  Previous pelvic or paraaortic lymphadenectomy.

          -  Previous having had pelvic radiation therapy.

          -  Ongoing treatment of arterial or venous insufficiency of the lower limbs

          -  Congenital or acquired malformations in the lymphatic system.

          -  Ongoing or previous treatment of lymphedema of the upper or lower limbs.

          -  Physically disability which impair mobilisation immediately postoperatively.

          -  Severe psychiatric disease and untreated mild/moderate psychiatric disease.

          -  Mentally retarded to a degree so she does not understand the meaning of the
             participation or cannot fill in the questionnaires.or the physician finds it ethically
             doubtful to enroll the patient in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Preben Kjölhede, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Obs/Gyn, University Hospital, Linköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Rosenberg, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Oncology, University Hospital, Linköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Lindahl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Oncology, University Hospital, Linköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Ahlner, RPT</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Oncology, University Hospital, Linköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janusz Marcickiewicz, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Obs/Gyn, Region Halland Varberg Hospital, Varberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Stålberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Obs/Gyn, Univeristy Hospital, Uppsala</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrika Ottander, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Norrlands University Hospital, Umeå</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristina Aglund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Oncology, Norrlands University Hospital, Umeå</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Åsa Åkesson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Sahlgrenska University Hospital, Göteborg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Blank, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Norra Älvsborg County Hospital in Trollhättan, Trollhättan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Högström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Södra Älvsborgs Hospital, Borås</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Rundqvist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Blekinge Hospital, Karlskrona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margareta Lood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Central Hospital, Karlstad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lotta Andreen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Central Hospital, Sundsvall</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Central Hospital, Gävle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Åsa Nyberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Central Hospital, Falun</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisbeth Liest, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Highland Hospital, Eksjö</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnel Lindell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Kalmar County Hospital, Kalmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Rosenmüller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obs/Gyn, Västervik County Hospital, Västervik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Preben Kjölhede, MD, PhD</last_name>
    <phone>+46101033187</phone>
    <email>Preben.Kjolhede@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Rosenberg, MD, PhD</last_name>
    <phone>+46101032017</phone>
    <email>Per.Rosenberg@regionostergotland.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Highland hospital</name>
      <address>
        <city>Eksjo</city>
        <state>Jonkopings län</state>
        <zip>57533</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Liest, MD</last_name>
      <phone>+4638135000</phone>
      <email>Lisbeth.Liest@rjl.se</email>
    </contact>
    <investigator>
      <last_name>Lisbeth Liest, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Falu Central Hospital</name>
      <address>
        <city>Falun</city>
        <zip>79182</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Åsa Nyberg, MD, PhD</last_name>
      <email>asa.nyberg@ltdalarna.se</email>
    </contact>
    <investigator>
      <last_name>Åsa Nyberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gävle County Hospital</name>
      <address>
        <city>Gävle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Smith, MD, PhD</last_name>
      <phone>+4626154165</phone>
      <email>peter.smith@lg.se</email>
    </contact>
    <investigator>
      <last_name>Peter Smith, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Åsa Åkesson, MD, PhD</last_name>
      <phone>+46313429234</phone>
      <email>asa.e.akesson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Åsa Åkesson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Region Halland Halmstad Hospital</name>
      <address>
        <city>Halmstad</city>
        <zip>30233</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Lindahl, MD, PhD</last_name>
      <phone>+4635147784</phone>
      <email>magnus.lindahl@regionhalland.se</email>
    </contact>
    <investigator>
      <last_name>Magnus Lindahl, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>County Hospital in Kalmar</name>
      <address>
        <city>Kalmar</city>
        <zip>39185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnel Lindell, MD, PhD</last_name>
      <email>Gunnel.Lindell@ltkalmar.se</email>
    </contact>
    <investigator>
      <last_name>Gunnel Lindell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blekinge Hospital</name>
      <address>
        <city>Karlskrona</city>
        <zip>37185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Rundqvist, MD, PhD</last_name>
      <phone>+46455174624</phone>
      <email>eva.rundqvist@ltblekinge.se</email>
    </contact>
    <investigator>
      <last_name>Eva Rundqvist, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karlstad Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margareta Lood, MD</last_name>
      <phone>+4654615144</phone>
      <email>margareta.lood@liv.se</email>
    </contact>
    <investigator>
      <last_name>Margareta Lood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linkoping University Hospital</name>
      <address>
        <city>Linkoping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preben Kjolhede, MD, PhD</last_name>
      <phone>+46101033187</phone>
      <email>Preben.Kjolhede@liu.se</email>
    </contact>
    <investigator>
      <last_name>Preben Kjolhede, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madelene Olsson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södra Älvborgs Sjukhus</name>
      <address>
        <city>Skövde</city>
        <zip>+4651085000</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Högström, MD, PhD</last_name>
      <phone>+4651085000</phone>
      <email>Lars.Hogstrom@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Lars Högström, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <zip>85186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lotta Andreén, MD, PhD</last_name>
      <phone>+4660181000</phone>
      <email>lotta.andreen@lvn.se</email>
    </contact>
    <investigator>
      <last_name>Lotta Andreén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norra Älvborgs Hospital</name>
      <address>
        <city>Trollhättan</city>
        <zip>46185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Blank, MD, PhD</last_name>
      <phone>+46104352264</phone>
      <email>eva.blank@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Eva Blank, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrlands University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrika Ottander, MD, PhD</last_name>
      <phone>+46907850000</phone>
      <email>ulrika.ottander@obgyn.umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Aglund, MD, PhD</last_name>
      <phone>+46907850000</phone>
      <email>kristina.aglund@vll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrika Ottander, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Aglund, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Stålberg, MD, PhD</last_name>
      <phone>+46186110000</phone>
      <email>Karin.Stalberg@kbh.uu.se</email>
    </contact>
    <investigator>
      <last_name>Karin Stålberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Region Halland Varberg hospital</name>
      <address>
        <city>Varberg</city>
        <zip>43281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Marcickiewicz, MD, PhD</last_name>
      <phone>+46340647990</phone>
      <email>Janusz.Marcickiewicz@regionhalland.se</email>
    </contact>
    <investigator>
      <last_name>Janusz Marcickiewicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västervik County Hospital</name>
      <address>
        <city>Västervik</city>
        <zip>59381</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Rosenmuller, MD</last_name>
      <phone>+4649086000</phone>
      <email>anders.rosenmuller@ltkalmar.se</email>
    </contact>
    <investigator>
      <last_name>Anders Rosenmuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Miller AJ, Bruna J, Beninson J. A universally applicable clinical classification of lymphedema. Angiology. 1999 Mar;50(3):189-92.</citation>
    <PMID>10088797</PMID>
  </reference>
  <reference>
    <citation>Sitzia J. Volume measurement in lymphoedema treatment: examination of formulae. Eur J Cancer Care (Engl). 1995 Mar;4(1):11-6.</citation>
    <PMID>7620649</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2014</study_first_submitted>
  <study_first_submitted_qc>April 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>February 20, 2016</last_update_submitted>
  <last_update_submitted_qc>February 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Preben Kjolhede, MD, professor</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Uterus cancer</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Lymphadenectomy</keyword>
  <keyword>Lymphedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

